Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Perdok

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology|April 1, 1997
Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgEJ Schuurman, G J Perdok, T E Lourens, et al.
Arthritis Research & Therapy|June 12, 2010
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPTDafna D Gladman, Philip J Mease, Ernest H S Choy, et al.
Immunology|August 24, 1999
Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sitesJ Schuurman, R Van Ree, G J Perdok, et al.
Allergy|July 1, 1993
Human proteins in house dustA M Witteman, J van Leeuwen, G J Perdok, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 25, 1998
Mouse/human chimeric IgG1 and IgG4 antibodies directed to the house dust mite allergen Der p 2: use in quantification of allergen specific IgGJ Schuurman, G J Perdok, G A Mueller, et al.
The Journal of Allergy and Clinical Immunology|January 1, 1996
The relationship between RAST and skin test results in patients with asthma or rhinitis: a quantitative study with purified major allergensA M Witteman, S O Stapel, G J Perdok, et al.
The Journal of Rheumatology|April 21, 2007
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapyMark C Genovese, Philip J Mease, Glen T D Thomson, et al.
Arthritis and Rheumatism|February 1, 2007
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trialDafna D Gladman, Philip J Mease, Christopher T Ritchlin, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Annals of the Rheumatic Diseases|August 8, 2008
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)P J Mease, P Ory, J T Sharp, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology|April 1, 1997
Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgEJ Schuurman, G J Perdok, T E Lourens, et al.
Arthritis Research & Therapy|June 12, 2010
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPTDafna D Gladman, Philip J Mease, Ernest H S Choy, et al.
Immunology|August 24, 1999
Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sitesJ Schuurman, R Van Ree, G J Perdok, et al.
Allergy|July 1, 1993
Human proteins in house dustA M Witteman, J van Leeuwen, G J Perdok, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 25, 1998
Mouse/human chimeric IgG1 and IgG4 antibodies directed to the house dust mite allergen Der p 2: use in quantification of allergen specific IgGJ Schuurman, G J Perdok, G A Mueller, et al.
The Journal of Allergy and Clinical Immunology|January 1, 1996
The relationship between RAST and skin test results in patients with asthma or rhinitis: a quantitative study with purified major allergensA M Witteman, S O Stapel, G J Perdok, et al.
The Journal of Rheumatology|April 21, 2007
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapyMark C Genovese, Philip J Mease, Glen T D Thomson, et al.
Arthritis and Rheumatism|February 1, 2007
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trialDafna D Gladman, Philip J Mease, Christopher T Ritchlin, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Annals of the Rheumatic Diseases|August 8, 2008
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)P J Mease, P Ory, J T Sharp, et al.
Pageof 3